Biomarkers come in many flavors and can be used as alternatives for assessing the functionality of therapeutics, mechanisms of action, predicting efficacy, monitoring toxicity, and stratification of patient populations. 16 of the 46 (34%) new molecular entities (NME) FDA approved in 2017 had an associated biomarker.
We at KCAS offer several different platforms for biomarker including, MSD, Luminex, SMCxPro, ELISA and flow cytometry. Our experience with a variety of matrices, including plasma, serum, CSF, soft tissues, hard tissues, sputum, and vitreous and aqueous humor enable us to support a wide range of therapeutic areas both non-clinical and clinical.
Clients come to KCAS because we help strategize which biomarkers to multiplex, the platform, and the level of regulation required. We also understand the challenges related to reagent procurement, endogenous levels, data tabulation, and bridging of reagents. Whether it’s for discovery biomarker screening for non-clinical samples or complementary/companion diagnostics for treatment of patients we have got you covered.
COMPOUND CLASSES
RELATED ASSAYS
- TBNK (CD16, CD56, CD19, CD25, CD14, CD4, CD8, CD3, HLA-DR, CD45)
- T subsets (CD45RA, CD197/CCR7, CD28, CD279/PD1, CD27, CD4, CD8, CD3, CD57, CD45)
- T reg intranuclear (CD45RA, CD25, CD39, CD4, FoxP3, CD3, Helios, CD45)
- TCR (TCR gamma-delta, TCR alpha-beta, HLA-DR, TCR Vdelta1, CD4, CD8, CD3, TCR Vdelta2, CD45)
- B cells (IgD, CD21, CD19, CD27, CD24, CD38, IgM, CD45)
- DCs (CD16, LINEAGE, CD1c, CD11c, Clee9A, CD123, HLA-DR, CD45)
- Intracellular (IFN gamma, TNF alpha, IL-2, CD8, CD3, CD4)
- DTC panel 1 (CD16, CD56, CD19, CD25, CD39, CD14, CD4, CD8, CD3, HLA-A2, CD45)
- DTC panel 2 (CD47, CD133, CD326, 7AAD, CD324, CD274, CD44, HLA-A2, CD45)
- ALL (CD7, CD79b, CD117, CD19, CD10, CD4, CD8, CD3, CD5, CD45)
- CLL (KAPPA, LAMBDA, CD117, CD19, CD10, CD20, CD23, CD43, CD5, CD45)
- MM1 (KAPPA, LAMBDA, CD48, CD56, CD117, CD138, CD38, CD33, CD19, CD45)
- MM2 (CD9, CD13, CD10, CD3, CD117, CD138, CD38, CD33, CD19, CD45)
- Histone DeAc (fixable L/D, H3 K27Ac, CD19, CD56, CD114, CD4, CD8, CD3, HLA-DR,DP,DQ, CD45)
- Total Tau
- Amyloid Beta 38 (Ab-38)
- Amyloid Beta 40 (Ab-40)
- Amyloid Beta 42 (Ab-42)
- Eotaxin
- Eotaxin-3
- Interleukin- 10 (IL-10)
- Interleukin- 12 (IL-12/IL-23p40)
- Interleukin- 13 (IL-13)
- Interleukin- 15 (IL-15)
- Interleukin- 16 (IL-16)
- Interleukin- 2 (IL-2)
- Interleukin- 5 (IL-5)
- Interleukin- 6 (IL-6)
- Interleukin- 7 (IL-7)
- Interleukin- 8 (IL-8(HA))
- Interleukin- 8 (IL-8)
- Interleukin-10 (IL-10)
- Interleukin-10 (IL-10)
- Interleukin-10 (IL-10)
- Interleukin-12 (IL-12p70)
- Interleukin-17A (IL-17A)
- Interleukin-1a (IL-1a)
- Interleukin-1b (IL-1b)
- Interleukin-4 (IL-4)
- Interferon alpha
- Interferon b1 (IFN-b1)
- Interferon g – inducible Protien -10 (IP-10)
- Interferon-g (IFN-g)
- Interferon-g (INF-g)
- Monocyte Chemotactic Protein 1 (MCP-1)
- Monocyte Chemotactic Protein 1 (MCP-1)
- Monocyte Chemotactic Protein 3 (MCP-3)
- Monocyte Chemotactic Protein 4 (MCP-4)
- Thymus Activation-Regulated Chemokine (TARC)
- Granulocyte Macrophage- Colony Stimulating Factor (GM-CSF)
- Tumor Necrosis Factor (TNF-a)
- Tumor Necrosis Factor (TNF-b)
- Vascular Endothelial Growth Factor (VEGF)